Literature DB >> 11956889

Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy.

Rakesh Bhattacharjee, G Filler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11956889     DOI： 10.1007/s00467-002-0829-y

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  11 in total

1.  Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.

Authors:  D Russo; R Minutolo; A Pisani; R Esposito; G Signoriello; M Andreucci; M M Balletta
Journal:  Am J Kidney Dis       Date:  2001-07       Impact factor: 8.860

2.  A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group.

Authors:  N Yoshikawa; H Ito; T Sakai; Y Takekoshi; M Honda; M Awazu; K Ito; K Iitaka; Y Koitabashi; K Yamaoka; K Nakagawa; H Nakamura; S Matsuyama; Y Seino; N Takeda; S Hattori; M Ninomiya
Journal:  J Am Soc Nephrol       Date:  1999-01       Impact factor: 10.121

Review 3.  Pathophysiology and treatment of IgA nephropathy in children.

Authors:  N Yoshikawa; R Tanaka; K Iijima
Journal:  Pediatr Nephrol       Date:  2001-05       Impact factor: 3.714

4.  Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy.

Authors:  D Russo; A Pisani; M M Balletta; L De Nicola; F A Savino; M Andreucci; R Minutolo
Journal:  Am J Kidney Dis       Date:  1999-05       Impact factor: 8.860

5.  Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.

Authors:  J Biollaz; H R Brunner; I Gavras; B Waeber; H Gavras
Journal:  J Cardiovasc Pharmacol       Date:  1982 Nov-Dec       Impact factor: 3.105

6.  Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart.

Authors:  H Urata; K D Boehm; A Philip; A Kinoshita; J Gabrovsek; F M Bumpus; A Husain
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

7.  Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study.

Authors:  J C Peterson; S Adler; J M Burkart; T Greene; L A Hebert; L G Hunsicker; A J King; S Klahr; S G Massry; J L Seifter
Journal:  Ann Intern Med       Date:  1995-11-15       Impact factor: 25.391

8.  Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy.

Authors:  D C Cattran; C Greenwood; S Ritchie
Journal:  Am J Kidney Dis       Date:  1994-02       Impact factor: 8.860

9.  Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up.

Authors:  B M Tune; R Kirpekar; R K Sibley; V M Reznik; W R Griswold; S A Mendoza
Journal:  Clin Nephrol       Date:  1995-02       Impact factor: 0.975

Review 10.  Levels of angiotensin and molecular biology of the tissue renin angiotensin systems.

Authors:  M I Phillips; E A Speakman; B Kimura
Journal:  Regul Pept       Date:  1993-01-22
View more
  11 in total

1.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

Review 2.  Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases.

Authors:  Shahid Nadeem; Donald L Batisky
Journal:  Pediatr Nephrol       Date:  2013-12-14       Impact factor: 3.714

3.  Angiotensin blockade in children with chronic glomerulonephritis and heavy proteinuria.

Authors:  Lavjay Butani
Journal:  Pediatr Nephrol       Date:  2005-08-16       Impact factor: 3.714

4.  Are we ready to use aliskiren in children?

Authors:  Erin Elizabeth Kelland; Leanne Michelle McAuley; Guido Filler
Journal:  Pediatr Nephrol       Date:  2010-12-11       Impact factor: 3.714

5.  Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.

Authors:  María Gracia Caletti; Alejandro Balestracci; Mabel Missoni; Clarisa Vezzani
Journal:  Pediatr Nephrol       Date:  2012-12-20       Impact factor: 3.714

Review 6.  Efficacy and safety of angiotensin II receptor type 1 antagonists in children and adolescents.

Authors:  Siegtraut Dorothea Herder; Ernst Weber; Almuth Winkemann; Christoph Herder; Hartmut Morck
Journal:  Pediatr Nephrol       Date:  2010-05       Impact factor: 3.714

7.  Treatment of Wilms tumor-related hypertension with losartan and captopril.

Authors:  William Wong; David Mauger
Journal:  Pediatr Nephrol       Date:  2004-05-06       Impact factor: 3.714

Review 8.  Isolated asymptomatic proteinuria.

Authors:  R N Srivastava
Journal:  Indian J Pediatr       Date:  2002-12       Impact factor: 1.967

9.  Enalapril in children with Alport syndrome.

Authors:  Willem Proesmans; Maria Van Dyck
Journal:  Pediatr Nephrol       Date:  2004-01-24       Impact factor: 3.714

Review 10.  Non-immunosuppressive therapies for childhood IgA nephropathy.

Authors:  Yuko Shima; Koichi Nakanishi; Norishige Yoshikawa
Journal:  Pediatr Nephrol       Date:  2021-02-16       Impact factor: 3.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.